The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

FDA Updates Efavirenz Labeling With Expanded Pediatric Indication Information

May 7, 2013

"On May 2, 2013, the FDA expanded the indication for Sustiva (efavirenz) to include pediatric patients at least three months old and weighing at least 3.5 kg. For pediatric patients who cannot swallow capsules, the capsule contents can be administered with a small amount of food or infant formula using the capsule sprinkle method of administration.

"The updated labeling includes a table for dosing along with the corresponding number of capsules or tablets and strength to administer."

Other sections of the label that have been updated include the following: Warnings and Precautions, Adverse Reactions, Pediatric Use, Pharmacokinetics, and Clinical Studies.

The updated labeling will be available at the FDA website.

More information is available:

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.
See Also
More on HIV Medications
More News on Efavirenz (Sustiva, Stocrin)

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: